艾伯维
ABBV
285.42
+2.02
+0.71%
艾伯维
US · ABBV
#30 按市值排名
上市于 1970
285.42
+2.02
+0.71%
实时 - 追踪5344个代码 - 心跳于473秒前
· 2026-10-16 20:02
✦ 量化股权信号 计算方式说明
减持
- 最近一期（2026/Q3）披露持股的机构数量减少了13家。
- 机构持股总比例基本持平。
机构持股
- 机构持股比例
- 76.71% -0.09pp
- 机构数量
- 4,742 -13
- 数据截至
- 2026/Q3 较上一报告期
持股变动 vs 资金流向
方向分歧机构在上一报告期减持了股份，同时该股在最近20个交易日的主力资金呈净流入——两者方向出现分歧。
机构持股变动数据按季度发布且存在滞后；资金流向数据为每日更新。请将其作为方向性的交叉验证参考，而非精确的择时信号。
持股人类型
Mutual Fund63.05%
Public Company5.38%
Private Company2.25%
Government Pension Fund2.00%
Sovereign Wealth Fund1.53%
Hedge Fund1.24%
Family Office/Trust0.51%
Insurance Company0.34%
Corporate Pension Plan0.19%
Other23.51%
主要股东 截至 2026-06-30
BlackRock
8.46% · 149.49M 股
Vanguard Capital Management, LLC
7.09% · 125.34M 股
State Street Global Advisors
4.67% · 82.60M 股
Capital Research
3.71% · 65.57M 股
Vanguard Portfolio Management, LLC
2.74% · 48.48M 股
Other
73.32%
Geode Capital Management, LLC
2.66% · 47.00M 股
J.P. Morgan Asset Management, Inc.
1.93% · 34.06M 股
UBS Asset Management
1.53% · 27.11M 股
Norges Bank Investment Management
1.45% · 25.55M 股
Morgan Stanley
1.35% · 23.81M 股
条形长度是相对于此处列出的最大股东而言，并非相对于公司100%股权。
内部人持股
共追踪50份申报 · 37次买入 · 13次卖出
| 姓名 | 职务 | 持股比例 |
|---|---|---|
| Richard Gonzalez | Chairperson & CEO | 0.02% |
| Azita Saleki | Chief Operating Officer | 0.01% |
| Robert Michael | President | 0.01% |
| Thomas Freyman | Independent Director | 0.01% |
| Jeffrey Stewart | Executive Vice President | 0.00% |
| Nicholas Donoghoe | Executive VP and Chief Business & Strategy Officer | 0.00% |
| Roopal Thakkar | SVP of Development & Regulatory Affairs and Chief Medical Officer | 0.00% |
| Scott Reents | Chief Financial Officer | 0.00% |
| Glenn Tilton | Lead Independent Director | 0.00% |
| Edward Rapp | Independent Director | 0.00% |
内部人交易 最近的 Form 4 申报记录
| 日期 | 姓名 | 职务 | 类型 | 股数 | 价格 |
|---|---|---|---|---|---|
| 2026-09-29 | Edward Rapp | Independent Director | Other Derivative Acquisition | +129 | $261.59 |
| 2026-09-29 | Susan Quaggin | Director | Other Derivative Acquisition | +59 | $261.59 |
| 2026-08-13 | Nicholas Donoghoe | Executive VP and Chief Business & Strategy Officer | Derivative Exercise and Sale | -32,710 | $79.02–250.00 |
| 2026-06-29 | Edward Rapp | Independent Director | Other Derivative Acquisition | +134 | $251.64 |
| 2026-06-29 | Susan Quaggin | Director | Other Derivative Acquisition | +62 | $251.64 |
| 2026-05-07 | Roxanne Austin | Independent Director | Other Acquisition | +1,118 | -- |
| 2026-05-07 | Thomas Freyman | Independent Director | Other Acquisition | +1,118 | -- |
| 2026-05-07 | Thomas Falk | Independent Director | Other Acquisition | +1,118 | -- |
| 2026-05-07 | Edward Rapp | Independent Director | Other Acquisition | +1,118 | -- |
| 2026-05-07 | William H. Burnside | Independent Director | Other Acquisition | +1,118 | -- |
| 2026-05-07 | Frederick Waddell | Independent Director | Other Acquisition | +1,118 | -- |
| 2026-05-07 | Melody Meyer | Independent Director | Other Acquisition | +1,118 | -- |
| 2026-05-07 | Brett Hart | Independent Director | Other Acquisition | +1,118 | -- |
| 2026-05-07 | Rebecca Roberts | Independent Director | Other Acquisition | +1,118 | -- |
| 2026-05-07 | Susan Quaggin | Director | Other Acquisition | +1,118 | -- |
| 2026-05-07 | Jennifer Davis | Director | Other Acquisition | +1,118 | -- |
| 2026-03-30 | Edward Rapp | Independent Director | Other Derivative Acquisition | +155 | $217.49 |
| 2026-03-30 | Robert Alpern | Independent Director | Other Derivative Acquisition | +35 | $217.49 |
| 2026-03-30 | Susan Quaggin | Director | Other Derivative Acquisition | +71 | $217.49 |
| 2026-03-03 | David Purdue | Senior Vice President & Controller | Open Market Disposition | -5,230 | $233.56 |
Form 4 申报记录，每家公司显示最新的一批。"Other Derivative Acquisition"（其他衍生品获取）类目多为限制性股票/期权归属，并非公开市场买入——具体类型见"类型"列。
报价时间 2026-10-16 20:02:32 · 仅供参考，不构成投资建议，也未考虑您的具体情况。
patent cliff fears priced in years ago and the new drugs stepped up more than skeptics expected. dividend yield here is still doing a lot of the work for the stock.